


# UBS Bond Euro High Yield

## Performance Review

UBS (Lux) Bond Fund - Euro High Yield (EUR) (RMB hedged) P-mdist



### Performance (basis CNH, net of fees)<sup>1</sup>



Past performance is not a reliable indicator of future results.

### Performance in % (net of fees)<sup>1</sup>

in %	2019	2020	2021	2022	2023 YTD <sup>2</sup>	Mar. 2023	5 years Ø p.a. 5 years
Fund (CNH)	13.66	4.22	6.39	-7.09	2.92	-0.72	18.95
Ref. Index <sup>3</sup>	14.91	5.96	7.15	-8.95	2.60	-0.38	22.06

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.

<sup>2</sup> YTD: year-to-date (since beginning of the year)

<sup>3</sup> Reference Index in currency of share class (without costs)

**Worries over the health of the banking system were the main preoccupation for investors in March. These concerns contributed to a sharp fall in government bond yields, with investors assuming that economic headwinds from the banking system would lead to an early end to rate hikes.**

### Monthly performance

In March the fund performed negatively with 0.7%. Yields on the EUR high-yield market ended the month marginally higher to finish at 7.45%. Spreads widened compared to last month.

### YTD performance

YTD as of the end of March, the fund has delivered a positive performance of 2.9%. Yields on the EUR high-yield market have moved lower and credit spreads have tightened in the year to date.

### Performance contributors

Positive contributors to performance included: (i) issue selection within food & drug retail; (ii) issue selection in homebuilders & real estate, which remains a highly volatile sector; and (iii) being overweight in healthcare, which is a more defensive sector by design.

### Performance detractors

The main detractor from performance was issue selection within financial services and banking, in particular our exposure to AT1, which traded down due to Credit Suisse bonds being written down after the acquisition by UBS. Other detractors included the overweights to food & drug retail and cable TV.

### For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Zachary Swabe

Jonathan Mather

Anais Brunner

# UBS Bond Euro High Yield

## Credit quality (%)

	Fund
BBB-&higher	5.4
BB+	14.1
BB	14.3
BB-	13.6
B+	10.5
B	17.9
B-	11.7
CCC+&lower	9.5
NR	0.5
Cash&Equivalents	2.5

## Categories of borrowers (%)

Sectors	Fund
Industrials	77.2
Financials	16.6
Utility	3.8
Cash & Equivalents	2.5
Others	-0.1

## 5 largest positions (%)

	Fund
Altice	3.9
Teva Pharmaceutical Industries Ltd	3.2
Nidda Healthcare Holding	3.1
Telecom Italia	2.7
Summer Bidco	2.7

## Current investment strategy

We increased our overweight to healthcare by adding to some existing issuers at the short end, while we lowered the overweight to diverse financial services, which was driven by reducing our holding in Intrum, the pan-European financial services company, and by exiting the AT1 Credit Suisse position. Finally, we reduced our off-benchmark exposure to energy, where we sold North Sea operators.

## Risks

Depending on the credit quality, the default risk is higher in the case of high yield bonds than with investment grade corporate and government bonds. Changes in interest rates have an effect on the value of the portfolio. This requires corresponding risk tolerance and capacity. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

This share class (mdist) may make monthly, gross-of-fee distributions. As a consequence, in addition to income, this share class may also distribute capital. This can have negative tax consequences for investors in some jurisdictions. Investors should seek their own tax advice.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, key information document, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available in a language required by the local applicable law free of charge from UBS Asset Management Switzerland AG, c/o UBS AG, Bahnhofstrasse 45, 8001 Zürich, Switzerland or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on [www.ubs.com/funds](http://www.ubs.com/funds). The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes all costs on the fund level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. A summary of investor rights in English can be found online at [www.ubs.com/funds](http://www.ubs.com/funds). More explanations of financial terms can be found at [www.ubs.com/am-glossary](http://www.ubs.com/am-glossary). © UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.